Sanofi(SNY) - 2021 Q2 - Quarterly Report

Exhibit 99.5 Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ³50% PD-L1 expression PARIS and TARRYTOWN, NY – June 25, 2021 - The European Commission (EC) has approved Sanofi and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer (NSCLC) whose tumor cells have ³50% PD-L1 expression and no EG ...